Prospective Study of Pravastatin in the Elderly at Risk
Initiatives
-
To investigate the benefits of treatment with pravastatin in elderly patients for whom a typical doctor might consider the prescription of statin therapy to be a realistic option. To examine the hypothesis that pravastatin, at a dose of 40 mg/day,
will reduce the risk of cardiovascular and cerebrovascular
events in elderly subjects with vascular disease
or at high risk of developing vascular disease.
*Note: All published information has been collected from the article referenced in the Marker Paper box below. Therefore, there may be variations with more advanced versions of the study.*
| Investigators | Contacts |
|---|---|
|
Design
- Study design
- Clinical trial cohort
- Follow Up
- Follow-up visits every 3 months for a minimim of 3 years.
Marker Paper
Shepherd J, Blauw GJ, Murphy MB, Cobbe SM, Bollen EL, Buckley BM, Ford I, Jukema JW, Hyland M, Gaw A, Lagaay AM, Perry IJ, Macfarlane PW, Meinders AE, Sweeney BJ, Packard CJ, Westendorp RG, Twomey C, Stott DJ. The design of a prospective study of Pravastatin in the Elderly at Risk (PROSPER). PROSPER Study Group. PROspective Study of Pravastatin in the Elderly at Risk. Am J Cardiol. 1999 Nov 15;84(10):1192-7. doi: 10.1016/s0002-9149(99)00533-0.
PUBMED 10569329
Recruitment
- Sources of Recruitment
-
- Individuals
Number of participants
- Number of participants
- 5,804
- Number of participants with biosamples
- Supplementary Information
- Cohort of men and women (70 to 82 years old)
Access
Availability of data and biosamples
| Data | |
| Biosamples | |
| Other |